|Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …|
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
|Screening for epidermal growth factor receptor mutations in lung cancer|
R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ...
New England Journal of Medicine 361 (10), 958-967, 2009
|Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non–small-cell lung cancer|
M Cobo, D Isla, B Massuti, A Montes, JM Sanchez, M Provencio, ...
Journal of clinical oncology 25 (19), 2747-2754, 2007
|Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients|
R Rosell, KD Danenberg, V Alberola, G Bepler, JJ Sanchez, C Camps, ...
Clinical Cancer Research 10 (4), 1318-1325, 2004
|Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group|
E Zucca, A Conconi, TI Mughal, AH Sarris, JF Seymour, U Vitolo, R Klasa, ...
Journal of Clinical Oncology 21 (1), 20-27, 2003
|Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations|
JM Silva, G Dominguez, JM Garcia, R Gonzalez, MJ Villanueva, ...
Cancer research 59 (13), 3251-3256, 1999
|Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients with EGFR mutations|
R Rosell, MA Molina, C Costa, S Simonetti, A Gimenez-Capitan, ...
Clinical Cancer Research 17 (5), 1160-1168, 2011
|Promoter methylation of the PTEN gene is a common molecular change in breast cancer|
JM García, J Silva, C Pena, V Garcia, R Rodríguez, MA Cruz, B Cantos, ...
Genes, Chromosomes and Cancer 41 (2), 117-124, 2004
|Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non–small-cell lung cancer: A Spanish Lung Cancer Group phase III …|
V Alberola, C Camps, M Provencio, D Isla, R Rosell, C Vadell, I Bover, ...
Journal of clinical oncology 21 (17), 3207-3213, 2003
|Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival|
J Silva, V García, A Zaballos, M Provencio, L Lombardía, L Almonacid, ...
European Respiratory Journal 37 (3), 617-623, 2011
|A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth …|
L Paz-Ares, JM Sanchez, A Garcia-Velasco, B Massuti, G Lopez-Vivanco, ...
Journal of Clinical Oncology 24 (18_suppl), 7020-7020, 2006
|Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression|
R Rosell, L Perez-Roca, JJ Sanchez, M Cobo, T Moran, I Chaib, ...
PloS one 4 (5), e5133, 2009
|Cancer antigen 125 associated with multiple benign and malignant pathologies|
C Miralles, M Orea, P Espana, M Provencio, A Sanchez, B Cantos, ...
Annals of Surgical Oncology 10 (2), 150-154, 2003
|Cancer‐associated fibroblast and M 2 macrophage markers together predict outcome in colorectal cancer patients|
M Herrera, A Herrera, G Domínguez, J Silva, V García, JM García, ...
Cancer science 104 (4), 437-444, 2013
|Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics|
JM Silva, G Dominguez, J Silva, JM Garcia, A Sanchez, O Rodriguez, ...
Clinical cancer research 7 (9), 2821-2825, 2001
|Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial|
C Camps, B Massuti, A Jimenez, I Maestu, RG Gómez, D Isla, ...
Annals of Oncology 17 (3), 467-472, 2006
|Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells|
JM Silva, R Rodriguez, JM Garcia, C Munoz, J Silva, G Dominguez, ...
Gut 50 (4), 530-534, 2002
|Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival|
JM Silva, J Silva, A Sanchez, JM Garcia, G Dominguez, M Provencio, ...
Clinical Cancer Research 8 (12), 3761-3766, 2002
|Aberrant DNA methylation of the p16 INK4a gene in plasma DNA of breast cancer patients|
JM Silva, G Dominguez, MJ Villanueva, R Gonzalez, JM Garcia, ...
British journal of cancer 80 (8), 1262-1264, 1999
|Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma|
A Sánchez-Aguilera, C Montalbán, P de la Cueva, L Sánchez-Verde, ...
Blood 108 (2), 662-668, 2006